Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29711529 | 0.73 | PTAFR (1.00) | PTAFR | |
| SCHEMBL3676278 | 0.60 | CYP3A4 (0.48) | PTAFRNLRP3 | |
| SCHEMBL3676277 | 0.60 | CYP3A4 (0.48) | PTAFRNLRP3 | |
| SCHEMBL21802956 | 0.59 | CYP3A4 (0.44) | PTAFRNLRP3 | |
| SCHEMBL9630684 | 0.59 | CYP3A4 (0.44) | PTAFRNLRP3 | |
| SCHEMBL9630691 | 0.59 | CYP3A4 (0.44) | PTAFRNLRP3 | |
| SCHEMBL9630687 | 0.59 | CYP3A4 (0.44) | PTAFRNLRP3 | |
| SCHEMBL272273 | 0.58 | CYP3A4 (0.46) | PTAFRNLRP3 | |
| SCHEMBL4615726 | 0.58 | CYP3A4 (0.46) | PTAFRNLRP3 | |
| SCHEMBL16268553 | 0.58 | CYP3A4 (0.46) | PTAFRNLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-11369566-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | ALK-ABELLÓ, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY INC (US) | 2022-02-10 | — | — | US | disclosed |
| WO-2010011609-A2 | CONTROLLED RELEASE ANTIMICROBIAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100021416-A1 | CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| WO-2010011605-A2 | CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010008995-A2 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016218-A1 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090324552-A1 | CONTROLLED RELEASE CYTOTOXIC AGENT COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325938-A1 | CONTROLLED-RELEASE CNS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090297533-A1 | CONTROLLED RELEASE IMMUNOMODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2009132050-A2 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016218-A1 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | BAX, BCL2, AIFM1 | PTAFR 280/4885NLRP3 3616/4885 |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | PTAFR 173/4885NLRP3 2614/4885 |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | PTAFR 173/4885NLRP3 2614/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | PTAFR 689/4885NLRP3 4414/4885 |
| US-20090325938-A1 | CONTROLLED-RELEASE CNS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTC, SLC18A2, PMP22 | PTAFR 484/4885NLRP3 4216/4885 |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | PTAFR 766/4885NLRP3 2849/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | PTAFR 173/4885NLRP3 2614/4885 |
| US-11369566-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | OTC, OAT, MYOC | PTAFR 1253/4885NLRP3 1391/4885 |
| US-20090324552-A1 | CONTROLLED RELEASE CYTOTOXIC AGENT COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTC, SLC47A2, SLC26A4 | PTAFR 708/4885NLRP3 4692/4885 |
| US-20100021416-A1 | CONTROLLED-RELEASE OTIC STRUCTURE MODULATING AND INNATE IMMUNE SYSTEM MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTC, TLR3, STING1 | PTAFR 291/4885NLRP3 279/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | PTAFR 689/4885NLRP3 4414/4885 |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | PTAFR 173/4885NLRP3 2614/4885 |
| US-20090297533-A1 | CONTROLLED RELEASE IMMUNOMODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTC, CD74, TSLP | PTAFR 377/4885NLRP3 3991/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | PTAFR 173/4885NLRP3 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.